Utilizing in silico tools (targetscan.org, http://diana.imis.athena-innovation.gr/ and microrna.org) we first identified putative miR-181a-binding sites in the 3′-untranslated regions (3′-UTRs) of KRAS, NRAS and MAPK1. In contrast, we could not identify putative miR-181a binding sites in the 3′-UTR of HRAS, which is rarely mutated in AML. This evidence concerns the gene NRAS and acute myeloid leukemia.